The Pharmaceutical Sciences and Pharmacogenomics Graduate Program (PSPG) is a cross-disciplinary program that consists of scientists at the University of California, San Francisco (UCSF) working in pharmaceutical sciences, computation and contemporary genetics. This Program encompasses the areas of molecular pharmacology related to drug development including: drug action, drug transport, drug metabolism and drug/gene delivery. The Program also includes the areas of pharmacokinetic/dynamic modeling, pharmacogenomics and bioinformatics applied to genetics/genomics. The Program offers training in these research areas through a core curriculum that encourages a breadth of knowledge about these fields and an elective curriculum that provides in-depth education on specific topics or techniques. Students participate in an ethical conduct in science course. The program immerses young scientists in the culture of science through a seminar program in pharmacogenomics, an annual retreat and seminars from industrial scientists. Students are recruited into the program with undergraduate degrees in the basic sciences and from Doctor of Pharmacy programs. There are 50 students in the program and approximately 10% of the students come from under represented groups. The program capacity was increased in 2000 from 35 students to 60 students and we anticipate reaching the 60 student capacity in 2012. There are 49 training faculty. Our program is one of the very few in the World with faculty expertise that spans the fields of pharmaceutics, genetics and computation;hence the training program is ideally situated to educate future scientific leaders in the emerging research areas at the intersection of these disciplines. The integrative approach has resulted in Ph.D. graduates who have the insights and quantitative scientific tools required for success in the rapidly advancing fields of drug development and pharmacogenomics;consequently graduates from the program are in high demand in academia, government and industry.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM007175-35
Application #
8101224
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Okita, Richard T
Project Start
1982-07-01
Project End
2012-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
35
Fiscal Year
2011
Total Cost
$289,973
Indirect Cost
Name
University of California San Francisco
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Chang, Matthew T; Penson, Alexander; Desai, Neil B et al. (2018) Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clin Cancer Res 24:1965-1973
Li, M; Seiser, E L; Baldwin, R M et al. (2018) ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia. Pharmacogenomics J 18:35-42
Rashkin, Sara R; Chua, Katherina C; Ho, Carol et al. (2018) A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance). Clin Pharmacol Ther :
Dolor, Aaron; Kierstead, Paul; Dai, Zhipeng et al. (2018) Sterol-modified PEG lipids: alteration of the bilayer anchoring moiety has an unexpected effect on liposome circulation. Chem Commun (Camb) 54:11949-11952
Vora, Bianca; Wang, Aolin; Kosti, Idit et al. (2018) Meta-Analysis of Maternal and Fetal Transcriptomic Data Elucidates the Role of Adaptive and Innate Immunity in Preterm Birth. Front Immunol 9:993
Yee, Sook Wah; Brackman, Deanna J; Ennis, Elizabeth A et al. (2018) Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium. Clin Pharmacol Ther 104:803-817
Rolt, Adam; Le, Derek; Hu, Zongyi et al. (2018) Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. J Infect Dis 217:1761-1769
Chan, Rosa; Benet, Leslie Z (2018) Evaluation of the Relevance of DILI Predictive Hypotheses in Early Drug Development: Review of In Vitro Methodologies vs BDDCS Classification. Toxicol Res (Camb) 7:358-370
Brackman, Deanna J; Giacomini, Kathleen M (2018) Reverse Translational Research of ABCG2 (BCRP) in Human Disease and Drug Response. Clin Pharmacol Ther 103:233-242
Li, Megan; Kroetz, Deanna L (2018) Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther 182:152-160

Showing the most recent 10 out of 193 publications